Given that increased glucagon secretion during DKA contributes to metabolic deterioration alongside insulin deficiency, therapeutic strategies targeting hyperglucagonemia—rather than focusing solely on hyperglycemia and insulin replacement—may offer additional clinical benefit. This evidence concerns the gene INS and Hyperglycemia.